3.Council of Ministers – Republic of Bulgaria (2016) .
4.Borissova, A-M et al. (2015) Changes in the prevalence of diabetes mellitus in Bulgaria (2006–2012). Clinical Medicine Insights: Endocrinology and Diabetes 8, 41–45.
7.Trauer, JM et al. (2017) Modular programming for tuberculosis control, the ‘AuTuMN’ platform. BMC Infectious Diseases 17, 546.
8.Cruz, AT and Starke, JR (2007) Clinical manifestations of tuberculosis in children. Paediatric Respiratory Reviews 8, 107–117.
9.Matlow, A, Robb, M and Goldman, C (2003) Infection control and paediatric tuberculosis: a practical guide for the practicing paediatrician. Paediatrics & Child Health 8, 624–626.
10.Tostmann, A et al. (2008) Tuberculosis transmission by patients with smear-negative pulmonary tuberculosis in a large cohort in the Netherlands. Clinical Infectious Diseases 47, 1135–1142.
11.Ragonnet, R et al. (2017) Optimally capturing latency dynamics in models of tuberculosis transmission. Epidemics 21, 39–47.
12.Trauer, JM et al. (2016) Risk of active tuberculosis in the five years following infection…15%? Chest 149, 516–525.
13.Jeon, CY and Murray, MB (2008) Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Medicine 5, e152.
14.Tiemersma, EW et al. (2011) Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review. PLoS One 6, e17601.
15.van Deun, A et al. (2010) Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. American Journal of Respiratory and Critical Care Medicine 182, 684–692.
16.Piubello, A et al. (2014) High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. The International Journal of Tuberculosis and Lung Disease 18, 1188–1194.
17.Kuaban, C et al. (2015) High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. The International Journal of Tuberculosis and Lung Disease 19, 517–524.
18.Aung, KJ et al. (2014) Successful ‘9-month Bangladesh regimen’ for multidrug-resistant tuberculosis among over 500 consecutive patients. The International Journal of Tuberculosis and Lung Disease 18, 1180–1187.
19.Martins, N, Morris, P and Kelly, PM (2009) Food incentives to improve completion of tuberculosis treatment: randomised controlled trial in Dili, Timor-Leste. BMJ 339, b4248.
20.Lutge, E et al. (2013) Economic support to improve tuberculosis treatment outcomes in South Africa: a pragmatic cluster-randomized controlled trial. Trials 14, 154.
21.Ciobanu, A et al. (2014) Do incentives improve tuberculosis treatment outcomes in the Republic of Moldova? Public Health in Action 4, 59–63.
22.Bassili, A et al. (2013) A systematic review of the effectiveness of hospital- and ambulatory-based management of multidrug-resistant tuberculosis. The American Journal of Tropical Medicine and Hygiene 89, 271–280.
23.Fitzpatrick, C and Floyd, K (2012) A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis. Pharmacoeconomics 30, 63–80.
24.Horter, S et al. (2014) ‘Home is where the patient is’: a qualitative analysis of a patient-centred model of care for multi-drug resistant tuberculosis. BMC Health Services 14, 81.
25.Williams, AO, Makinde, OA and Ojo, M (2016) Community-based management vs. traditional hospitalization in treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. Global Health Research and Policy 1, 10.
26.Dye, C et al. (2013) Prospects for tuberculosis elimination. The Annual Review of Public Health 34, 271–286.
27.Hill, PC et al. (2014) Mass treatment to eliminate tuberculosis from an island population. The International Journal of Tuberculosis and Lung Disease 18, 899–904.
28.Ragonnet, R et al. (2017) Is IPT more effective in high-burden settings? Modelling the effect of tuberculosis incidence on IPT impact. The International Journal of Tuberculosis and Lung Disease 21, 60–66.
29.Houben, RM et al. (2016) TIME impact – a new user-friendly tuberculosis (TB) model to inform TB policy decisions. BMC Medicine 14, 56.